Despite volume lag, drug firms hike price as domestic sales rebound

Motilal Oswal analysts also said that while price growth for non-NLEM products stood at 4.8 per cent YoY, NLEM products saw a price rise of 3.6 per cent

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab

Domestic pharma sales bounced back in September, but what’s interesting is that this rise was led by pricing growth.   During the pandemic — when people are avoiding hospitals and clinics and fresh prescription growth has slowed down — the volume growth in the domestic market has also fallen. However, a deeper look at the data shows that the volume decline too has been slowing — it fell 4 per cent year-on-year in September against 9.2 per cent decline in August.   Motilal Oswal analysts said for the September quarter, while the volumes fell 6.5 ...